Payment overview · 2025
General Payments
$1,454.00
66 reported records · 20 companies
Healthcare provider profile · identity verified
Boris Vaisman, MD
Allopathic & Osteopathic Physicians|Family Medicine · WOODLAND HILLS, CA · NPI 1508801994
Verified facts
What the public records show
CMS Open Payments records show Boris Vaisman, MD received $1,454.00 in general payments during 2025 across 66 reported records.
ABBVIE INC. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $610.16 | 42.0% | 30 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $104.11 | 7.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.23 | 6.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.87 | 5.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.74 | 4.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.58 | 4.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $60.53 | 4.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.39 | 3.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.71 | 3.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.38 | 2.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.99 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.59 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.83 | 1.9% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $25.94 | 1.8% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.33 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.29 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.86 | 1.6% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.36 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.52 | 1.3% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.59 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,454.00 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $248.97 | 11 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $184.56 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.54 | 8 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $176.28 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $174.64 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $104.11 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.87 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.58 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.58 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $60.53 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.19 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $48.76 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $47.71 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.04 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.64 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 109 |
| Omeprazole | Omeprazole | 241 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 75 |
| Losartan Potassium | Losartan Potassium | 219 | 78 |
| Metformin Hcl | Metformin Hcl | 203 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 186 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 31 |
| Gabapentin | Gabapentin | 149 | 42 |
| Montelukast Sodium | Montelukast Sodium | 144 | 32 |
| Lisinopril | Lisinopril | 138 | 45 |
| Meloxicam | Meloxicam | 129 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 116 | 37 |
| Alprazolam | Alprazolam | 115 | 27 |
| Trazodone Hcl | Trazodone Hcl | 111 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 32 |
| Ibuprofen | Ibuprofen | 105 | 21 |
| Tramadol Hcl | Tramadol Hcl | 102 | 25 |
| Lorazepam | Lorazepam | 99 | 26 |
| Furosemide | Furosemide | 95 | 22 |
| Potassium Chloride | Potassium Chloride | 95 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 12 |
| Carvedilol | Carvedilol | 85 | 27 |
| Simvastatin | Simvastatin | 84 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 23 |
| Sertraline Hcl | Sertraline Hcl | 79 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 72 | 22 |
| Pregabalin | Pregabalin | 71 | 11 |
| Allopurinol | Allopurinol | 70 | 17 |
| Jardiance | Empagliflozin | 67 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 12 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 65 | suppressed |
| Spironolactone | Spironolactone | 64 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 63 | 18 |
| Bupropion Xl | Bupropion Hcl | 62 | 25 |
| Ozempic | Semaglutide | 62 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 61 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 21 |
| Meclizine Hcl | Meclizine Hcl | 56 | 13 |
| Celecoxib | Celecoxib | 55 | suppressed |
| Eliquis | Apixaban | 54 | 13 |
| Fenofibrate | Fenofibrate | 54 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Atenolol | Atenolol | 51 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 47 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Vascepa | Icosapent Ethyl | 46 | suppressed |
| Nystatin | Nystatin | 44 | 16 |
| Valacyclovir | Valacyclovir Hcl | 44 | 14 |
| Linzess | Linaclotide | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 11 |
| Famotidine | Famotidine | 40 | 11 |
| Temazepam | Temazepam | 40 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Creon | Lipase/Protease/Amylase | 38 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Naproxen | Naproxen | 34 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 11 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | 11 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Finasteride | Finasteride | 29 | 11 |
| Synthroid | Levothyroxine Sodium | 29 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Metformin Hcl Er | Metformin Hcl | 24 | 12 |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Prednisone | Prednisone | 23 | 21 |
| Azithromycin | Azithromycin | 22 | 20 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | 12 |
| Fluocinonide | Fluocinonide | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Jublia | Efinaconazole | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,454.00 · 66 records | ABBVIE INC. | AIRSUPRA, AMVUTTRA, APLENZIN, BREZTRI, CAPVAXIVE, CREON, Flector, GARDASIL 9, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Licart, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, WELLBUTRIN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error